Cognitive enhancement treatments for bipolar disorder: A systematic review and methodological recommendations

European Neuropsychopharmacology

Volumn 26, Issue 10, 2016, Pages 1541-1561

  Miskowiak, Kamilla W ^a   Carvalho, André F ^b   Vieta, Eduard ^c   Kessing, Lars V ^a  

^a Rigshospitalet   (Denmark)

^b FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Bipolar disorder; Cognitive dysfunction; Cognitive enhancement; Intervention; Randomized controlled trials; Systematic review

Indexed keywords

ACETYLCYSTEINE; ARMODAFINIL; CITICOLINE; DONEPEZIL; GALANTAMINE; INSULIN; MIFEPRISTONE; MODAFINIL; PLACEBO; PRAMIPEXOLE; PREGNENOLONE; RECOMBINANT ERYTHROPOIETIN; WITHANIA SOMNIFERA EXTRACT; NOOTROPIC AGENT;

BIPOLAR DISORDER; CLINICAL TRIAL (TOPIC); COCHRANE LIBRARY; COGNITION; COGNITION ASSESSMENT; COGNITIVE DEFECT; COGNITIVE REMEDIATION THERAPY; COGNITIVE THERAPY; CONSENSUS; HUMAN; MEDLINE; MENTAL PATIENT; MILD COGNITIVE IMPAIRMENT; MULTICENTER STUDY (TOPIC); OPEN STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; PSYCINFO; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT OUTCOME; WITHANIA SOMNIFERA; META ANALYSIS; PSYCHOLOGY;

BIPOLAR DISORDER; GUIDELINES AS TOPIC; HUMANS; NOOTROPIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84991060669     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2016.08.011     Document Type: Review

References (61)

1. Barch, D.M., Neuropsychological abnormalities in schizophrenia and major mood disorders: similarities and differences. Curr. Psychiatry Rep. 11 (2009), 313–319.
2. Bonnin, C.M., Martinez-Aran, A., Torrent, C., Pacchiarotti, I., Rosa, A.R., Franco, C., Murru, A., Sanchez-Moreno, J., Vieta, E., Clinical and neurocognitive predictors of functional outcome in bipolar euthymic patients: a long-term, follow-up study. J. Affect. Disord. 121 (2010), 156–160.
3. Bonnin, C.M., Reinares, M., Martinez-Aran, A., Balanza-Martinez, V., Sole, B., Torrent, C., Tabares-Seisdedos, R., Garcia-Portilla, M.P., Ibanez, A., Amann, B.L., Arango, C., Ayuso-Mateos, J.L., Crespo, J.M., Gonzalez-Pinto, A., Colom, F., Vieta, E., Effects of functional remediation on neurocognitively impaired bipolar patients: enhancement of verbal memory. Psychol. Med., 2015, 1–11.
4. Bora, E., Yucel, M., Pantelis, C., Cognitive endophenotypes of bipolar disorder: a meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. J. Affect. Disord. 113 (2009), 1–20.
5. Bortolato, B., Miskowiak, K.W., Kohler, C.A., Maes, M., Fernandes, B.S., Berk, M., Carvalho, A.F., Cognitive remission: a novel objective for the treatment of major depression?. BMC. Med., 14, 2016, 9.
6. Bourne, C., Aydemir, O., Balanza-Martinez, V., Bora, E., Brissos, S., Cavanagh, J.T., Clark, L., Cubukcuoglu, Z., Dias, V.V., Dittmann, S., Ferrier, I.N., Fleck, D.E., Frangou, S., Gallagher, P., Jones, L., Kieseppa, T., Martinez-Aran, A., Melle, I., Moore, P.B., Mur, M., Pfennig, A., Raust, A., Senturk, V., Simonsen, C., Smith, D.J., Bio, D.S., Soeiro-de-Souza, M.G., Stoddart, S.D., Sundet, K., Szoke, A., Thompson, J.M., Torrent, C., Zalla, T., Craddock, N., Andreassen, O.A., Leboyer, M., Vieta, E., Bauer, M., Worhunsky, P.D., Tzagarakis, C., Rogers, R.D., Geddes, J.R., Goodwin, G.M., Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis. Acta Psychiatr. Scand. 128 (2013), 149–162.
7. Brown, E.S., Gabrielson, B., A randomized, double-blind, placebo-controlled trial of citicoline for bipolar and unipolar depression and methamphetamine dependence. J. Affect. Disord. 143 (2012), 257–260.
8. Brown, E.S., Gorman, A.R., Hynan, L.S., A randomized, placebo-controlled trial of citicoline add-on therapy in outpatients with bipolar disorder and cocaine dependence. J. Clin. Psychopharmacol. 27 (2007), 498–502.
9. Burdick, K.E., Braga, R.J., Nnadi, C.U., Shaya, Y., Stearns, W.H., Malhotra, A.K., Placebo-controlled adjunctive trial of pramipexole in patients with bipolar disorder: targeting cognitive dysfunction. J. Clin. Psychiatry 73 (2012), 103–112.
10. Burdick, K.E., Ketter, T.A., Goldberg, J.F., Calabrese, J.R., Assessing cognitive function in bipolar disorder: challenges and recommendations for clinical trial design. J. Clin. Psychiatry 76 (2015), e342–e350.
11. Burdick, K.E., Russo, M., Frangou, S., Mahon, K., Braga, R.J., Shanahan, M., Malhotra, A.K., Empirical evidence for discrete neurocognitive subgroups in bipolar disorder: clinical implications. Psychol. Med. 44 (2014), 3083–3096.
12. Chengappa, K.N., Bowie, C.R., Schlicht, P.J., Fleet, D., Brar, J.S., Jindal, R., Randomized placebo-controlled adjunctive study of an extract of withania somnifera for cognitive dysfunction in bipolar disorder. J. Clin. Psychiatry 74 (2013), 1076–1083.
13. Dean, O.M., Bush, A.I., Copolov, D.L., Kohlmann, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., Berk, M., Effects of N-acetyl cysteine on cognitive function in bipolar disorder. Psychiatry Clin. Neurosci. 66 (2012), 514–517.
14. Deckersbach, T., Nierenberg, A.A., Kessler, R., Lund, H.G., Ametrano, R.M., Sachs, G., Rauch, S.L., Dougherty, D., RESEARCH: Cognitive rehabilitation for bipolar disorder: An open trial for employed patients with residual depressive symptoms. CNS. Neurosci. Ther. 16 (2010), 298–307.
15. Demant, K.M., Vinberg, M., Kessing, L.V., Miskowiak, K.W., Assessment of subjective and objective cognitive function in bipolar disorder: Correlations, predictors and the relation to psychosocial function. Psychiatry Res. 229 (2015), 565–571.
16. Demant, K.M., Vinberg, M., Kessing, L.V., Miskowiak, K.W., Effects of short-term cognitive remediation on cognitive dysfunction in partially or fully remitted individuals with bipolar disorder: results of a randomised controlled trial. PLOS ONE, 10, 2015, e0127955.
17. Demirtas-Tatlidede, A., Vahabzadeh-Hagh, A.M., Pascual-Leone, A., Can noninvasive brain stimulation enhance cognition in neuropsychiatric disorders?. Neuropharmacology 64 (2013), 566–578.
18. Dias, V.V., Balanza-Martinez, V., Soeiro-de-Souza, M.G., Moreno, R.A., Figueira, M.L., Machado-Vieira, R., Vieta, E., Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview. Acta Psychiatr. Scand. 126 (2012), 315–331.
19. Forcada, I., Mur, M., Mora, E., Vieta, E., Bartres-Faz, D., Portella, M.J., The influence of cognitive reserve on psychosocial and neuropsychological functioning in bipolar disorder. Eur. Neuropsychopharmacol. 25 (2015), 214–222.
20. Ghaemi, S.N., Gilmer, W.S., Dunn, R.T., Hanlon, R.E., Kemp, D.E., Bauer, A.D., Chriki, L., Filkowski, M.M., Harvey, P.D., A double-blind, placebo-controlled pilot study of galantamine to improve cognitive dysfunction in minimally symptomatic bipolar disorder. J. Clin. Psychopharmacol. 29 (2009), 291–295.
21. Gildengers, A.G., Butters, M.A., Chisholm, D., Reynolds, C.F., Mulsant, B.H., A 12-week open-label pilot study of donepezil for cognitive functioning and instrumental activities of daily living in late-life bipolar disorder. Int. J. Geriatr. Psychiatry 23 (2008), 693–698.
22. Grande, I., Berk, M., Birmaher, B., Vieta, E., Bipolar disorder. Lancet, 2015.
23. Higgins, J.P., Green, S. 2011. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration.
24. Iosifescu, D.V., Moore, C.M., Deckersbach, T., Tilley, C.A., Ostacher, M.J., Sachs, G.S., Nierenberg, A.A., Galantamine-ER for cognitive dysfunction in bipolar disorder and correlation with hippocampal neuronal viability: a proof-of-concept study. CNS. Neurosci. Ther. 15 (2009), 309–319.
25. Jensen, J.H., Knorr, U., Vinberg, M., Kessing, L.V., Miskowiak, K.W. 2016. Discrete neurocognitive subgroups in fully or partially remitted bipolar disorder. in press.
26. Jensen, J.H., Støttrup, M.M., Nayberg, E., Knorr, U., Ullum, H., Purdon, S.E., Kessing, L.V., Miskowiak, K.W., Optimising screening for cognitive dysfunction in bipolar disorder: validation and evaluation of objective and subjective tools. J. Affect Disord., 187, 2015, 19.
27. Kessing, L.V., Andersen, P.K., Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder?. J. Neurol. Neurosurg. Psychiatry 75 (2004), 1662–1666.
28. Kessing, L.V., Vradi, E., Andersen, P.K., Starting lithium prophylaxis early v. late in bipolar disorder. Br. J. Psychiatry 205 (2014), 214–220.
29. Martinez-Aran, A., Vieta, E., Cognition as a target in schizophrenia, bipolar disorder and depression. Eur. Neuropsychopharmacol. 25 (2015), 151–157.
30. Martinez-Aran, A., Vieta, E., Colom, F., Torrent, C., Reinares, M., Goikolea, J.M., Benabarre, A., Comes, M., Sanchez-Moreno, J., Do cognitive complaints in euthymic bipolar patients reflect objective cognitive impairment?. Psychother. Psychosom. 74 (2005), 295–302.
31. McIntyre, R.S., Lophaven, S., Olsen, C.K., A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int. J. Neuropsychopharmacol., 2014, 1–11.
32. McIntyre, R.S., Soczynska, J.K., Woldeyohannes, H.O., Miranda, A., Vaccarino, A., Macqueen, G., Lewis, G.F., Kennedy, S.H., A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder. Bipolar. Disord. 14 (2012), 697–706.
33. Meusel, L.A., Cognitive remediation in patients with mood disorders: behavioural and neural correlates. In (Anonymous), 2011, McMaster University, 45–46.
34. Meusel, L.A., Hall, G.B., Fougere, P., McKinnon, M.C., MacQueen, G.M., Neural correlates of cognitive remediation in patients with mood disorders. Psychiatry Res. 214 (2013), 142–152.
35. Millan, M.J., Agid, Y., Brune, M., Bullmore, E.T., Carter, C.S., Clayton, N.S., Connor, R., Davis, S., Deakin, B., DeRubeis, R.J., Dubois, B., Geyer, M.A., Goodwin, G.M., Gorwood, P., Jay, T.M., Joels, M., Mansuy, I.M., Meyer-Lindenberg, A., Murphy, D., Rolls, E., Saletu, B., Spedding, M., Sweeney, J., Whittington, M., Young, L.J., Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat. Rev. Drug Discov. 11 (2012), 141–168.
36. Miskowiak, K.W., Ehrenreich, H., Christensen, E.M., Kessing, L.V., Vinberg, M., Recombinant human erythropoietin to target cognitive dysfunction in bipolar disorder: a double-blind, randomized, placebo-controlled phase 2 trial. J. Clin. Psychiatry, 2014.
37. Miskowiak, K.W., Rush, A.J., Gerds, T.A., Vinberg, M., Kessing, L.V. 2015. Targeting treatments to improve cognitive function in mood disorder: Suggestions from trials using erythropoietin. in press.
38. Miskowiak, K.W., Vinberg, M., Christensen, E.M., Bukh, J.D., Harmer, C.J., Ehrenreich, H., Kessing, L.V., Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial. Neuropsychopharmacology 39 (2014), 1399–1408.
39. Miskowiak, K.W., Vinberg, M., Harmer, C.J., Ehrenreich, H., Kessing, L.V., Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression. Psychopharmacol. (Berl.) 219 (2012), 687–698.
40. Mur, M., Portella, M.J., Martinez-Aran, A., Pifarre, J., Vieta, E., Influence of clinical and neuropsychological variables on the psychosocial and occupational outcome of remitted bipolar patients. Psychopathology 42 (2009), 148–156.
41. Naismith, S.L., Redoblado-Hodge, M.A., Lewis, S.J., Scott, E.M., Hickie, I.B., Cognitive training in affective disorders improves memory: a preliminary study using the NEAR approach. J. Affect. Disord. 121 (2010), 258–262.
42. Nathan, P.J., Phan, K.L., Harmer, C.J., Mehta, M.A., Bullmore, E.T., Increasing pharmacological knowledge about human neurological and psychiatric disorders through functional neuroimaging and its application in drug discovery. Curr. Opin. Pharmacol. 14 (2014), 54–61.
43. Osuji, I.J., Vera-Bolanos, E., Carmody, T.J., Brown, E.S., Pregnenolone for cognition and mood in dual diagnosis patients. Psychiatry Res 178 (2010), 309–312.
44. Ott, C.V., Vinberg, M., Kessing, L.V., Miskowiak, K.W., The effect of erythropoietin on cognition in affective disorders - associations with baseline deficits and change in subjective cognitive complaints. Eur Neuropsychopharmacol. 26:8 (2016), 1264–1273.
45. Preiss, M., Kucerova, H., Lukavsky, J., Stepankova, H., Sos, P., Kawaciukova, R., Cognitive deficits in the euthymic phase of unipolar depression. Psychiatry Res. 169 (2009), 235–239.
46. Preiss, M., Shatil, E., Cermakova, R., Cimermanova, D., Ram, I., Personalized cognitive training in unipolar and bipolar disorder: a study of cognitive functioning. Front Hum. Neurosci., 7, 2013, 108.
47. Reichenberg, A., Harvey, P.D., Bowie, C.R., Mojtabai, R., Rabinowitz, J., Heaton, R.K., Bromet, E., Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders. Schizophr. Bull. 35 (2009), 1022–1029.
48. Rosa, A.R., Magalhaes, P.V., Czepielewski, L., Sulzbach, M.V., Goi, P.D., Vieta, E., Gama, C.S., Kapczinski, F., Clinical staging in bipolar disorder: focus on cognition and functioning. J. Clin. Psychiatry 75 (2014), e450–e456.
49. Schaefer, J., Giangrande, E., Weinberger, D.R., Dickinson, D., The global cognitive impairment in schizophrenia: consistent over decades and around the world. Schizophr. Res. 150 (2013), 42–50.
50. Schretlen, D.J., Cascella, N.G., Meyer, S.M., Kingery, L.R., Testa, S.M., Munro, C.A., Pulver, A.E., Rivkin, P., Rao, V.A., Diaz-Asper, C.M., Dickerson, F.B., Yolken, R.H., Pearlson, G.D., Neuropsychological functioning in bipolar disorder and schizophrenia. Biol. Psychiatry 62 (2007), 179–186.
51. Sole, B., Jimenez, E., Martinez-Aran, A., Vieta, E., Cognition as a target in major depression: new developments. Eur. Neuropsychopharmacol. 25 (2015), 231–247.
52. Torrent, C., Bonnin, C.M., Martinez-Aran, A., Valle, J., Amann, B.L., Gonzalez-Pinto, A., Crespo, J.M., Ibanez, A., Garcia-Portilla, M.P., Tabares-Seisdedos, R., Arango, C., Colom, F., Sole, B., Pacchiarotti, I., Rosa, A.R., Ayuso-Mateos, J.L., Anaya, C., Fernandez, P., Landin-Romero, R., Alonso-Lana, S., Ortiz-Gil, J., Segura, B., Barbeito, S., Vega, P., Fernandez, M., Ugarte, A., Subira, M., Cerrillo, E., Custal, N., Menchon, J.M., Saiz-Ruiz, J., Rodao, J.M., Isella, S., Alegria, A., Al-Halabi, S., Bobes, J., Galvan, G., Saiz, P.A., Balanza-Martinez, V., Selva, G., Fuentes-Dura, I., Correa, P., Mayoral, M., Chiclana, G., Merchan-Naranjo, J., Rapado-Castro, M., Salamero, M., Vieta, E., Efficacy of functional remediation in bipolar disorder: a multicenter randomized controlled study. Am. J. Psychiatry 170 (2013), 852–859.
53. Torrent, C., Martinez-Aran, A., del Mar, B.C., Reinares, M., Daban, C., Sole, B., Rosa, A.R., Tabares-Seisdedos, R., Popovic, D., Salamero, M., Vieta, E., Long-term outcome of cognitive impairment in bipolar disorder. J. Clin. Psychiatry 73 (2012), e899–e905.
54. Tse, S., Chan, S., Ng, K.L., Yatham, L.N., Meta-analysis of predictors of favorable employment outcomes among individuals with bipolar disorder. Bipolar. Disord. 16 (2014), 217–229.
55. Vieta, E., Staging and psychosocial early intervention in bipolar disorder. Lancet Psychiatry 2 (2015), 483–485.
56. Vieta, E., Reinares, M., Rosa, A.R., Staging bipolar disorder. Neurotox. Res. 19 (2011), 279–285.
57. Vinberg, M., Miskowiak, K.W., Kessing, L.V., Impairment of executive function and attention predicts onset of affective disorder in healthy high-risk twins. J. Clin. Psychiatry 74 (2013), e747–e753.
58. Vreeker, A., van Bergen, A.H., Kahn, R.S., Cognitive enhancing agents in schizophrenia and bipolar disorder. Eur. Neuropsychopharmacol. 25 (2015), 969–1002.
59. Watson, S., Gallagher, P., Porter, R.J., Smith, M.S., Herron, L.J., Bulmer, S., Young, A.H., Ferrier, I.N., A randomized trial to examine the effect of mifepristone on neuropsychological performance and mood in patients with bipolar depression. Biol. Psychiatry 72 (2012), 943–949.
60. Wykes, T., Huddy, V., Cellard, C., McGurk, S.R., Czobor, P., A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am. J. Psychiatry 168 (2011), 472–485.
61. Young, A.H., Gallagher, P., Watson, S., Del-Estal, D., Owen, B.M., Ferrier, I.N., Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology 29 (2004), 1538–1545.